Global 5HT3 Receptor Antagonists Market is Segmented by Product type(First Generation(Dolasetron, Granisetron, Ondansetron) and Second Generation(Palonosetron), By Application(CINV, RINV and PONV) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global "5HT3 Receptor Antagonists Market" is predicted to reach at a high CAGR during the forecast period (2022-2029).
It is a type of drug used to treat certain types of irritable bowel syndrome and relieve nausea and vomiting. It is an antiemetic.
Market Dynamics
An increase in the prevalence of cancer is expected to drive the market's growth.
According to the Journal, it is estimated 54,010 adults (38,800 men and 15,210 women) in the United States will be diagnosed with oral and oropharyngeal cancer. Moreover, if the cancer is diagnosed early, all people's overall 5-year survival rate is 85%. About 29% of oral and oropharyngeal cancers are diagnosed at this stage. Additionally, if cancer has spread to surrounding tissues or organs or the regional lymph nodes, the overall 5-year survival rate is 67%, and almost half of cases are diagnosed at this stage. If cancer has spread to a distant part of the body, the overall 5-year survival rate is 40%. Most oropharyngeal cancers are caused by HPV infection, smoking or tobacco use and heavy alcohol consumption.
Therefore, antiemetic therapy is crucial for patients undergoing chemotherapy or radiotherapy for cancer. Severe nausea and vomiting associated with cancer treatment can lead to anxiety, anorexia, dehydration, electrolyte disturbance and renal failure. They may interrupt cancer therapy, demoralize patients or even cause them to abandon treatment. Several selective 5HT3-receptor antagonists are licensed(i.e.: ondansetron, the first selective serotonin type 3- (5HT3-) receptor antagonist). Thus increasing cases of cancer have driven the market in the forecast period.
Side-Effects Associated with the use of the drug is expected to hamper the market's growth.
According to the article, on Oct 26, 2020. Granisetron is used to prevent nausea and vomiting caused by surgery, cancer chemotherapy, or radiation treatment. Every drug has its benefits. It even has side effects, including diarrhea, constipation, stomach pain or upset, loss of appetite, weakness, headache, fever, dizziness, drowsiness, trouble sleeping (insomnia), and anxiety. Thus, from the above factors, the market is expected to hamper the market's growth in the forecast period.
COVID-19 Impact Analysis
The coronavirus disease 2019 pandemic has affected millions of people worldwide and severely disrupted the delivery of health care. Recent studies have demonstrated that patients with preexisting cardiovascular disease and cancer are at increased risk of infection and life-threatening complications due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, there has been a high prevalence of cardiovascular comorbidities among patients with COVID-19, particularly those with severe disease. Recent case series also report a significant increase in severe outcomes and case fatalities among patients with cancer with COVID-19. Based on these, cardio-oncology patients are likely to be particularly susceptible to poor outcomes from COVID-19 given their compromised immune system and limited cardiopulmonary reserve related to coexistent cancer and cardiovascular disease.
In addition, the pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. However, the situation is expected to improve gradually in the forecast period.
Segment Analysis
The second generation segment is expected to hold the largest market share in this market segment.
The second-generation segment accounted for the largest market share in 2020. The segment's growth is benefited because the newer drug palonosetron is a pharmacologically distinct and highly selective, second-generation 5-HT3 receptor antagonist and has a longer half-life (40h) and greater receptor binding affinity. Moreover, it is used to prevent nausea and vomiting caused by cancer medicines (chemotherapy). It is used to prevent nausea and vomiting that may occur after surgery. It works by blocking the signals to the brain that cause nausea and vomiting. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Geographical Share
North America region holds the largest market share in the global 5HT3 receptor antagonists market.
North America dominated the market and led to the largest revenue share in 2020. The region's growth is attributed to the ongoing technological advancement in the region. The presence of leading healthcare companies, raising cases of surgeries and the high prevalence of chronic diseases such as diabetes is expected to boost the market in the forecast period. For instance, according to the article, on 11 February 2021, diabetes is a serious and increasingly common chronic disease that can cause devastating complications that often result in disability and death. As early detection, improved delivery of care and better self-management are key strategies for preventing much of the burden of diabetes. Type 2 diabetes, formerly considered adult-onset diabetes, is now being diagnosed more commonly seen among children and adolescents. This type of diabetes is linked to two modifiable risk factors obesity and physical inactivity.
Moreover, 34.2 million Americans—just over 1 in 10—have diabetes, and 88 million American adults—approximately 1 in 3—have prediabetes. Newly diagnosed cases of type 1 and type 2 diabetes have significantly increased among US youth. For ages 10 to 19 years, the incidence of type 2 diabetes remained stable among non-Hispanic whites and increased for all others, especially non-Hispanic blacks. Thus, the region is expected to hold the largest market region in the forecast period from the above statements.
Competitive Landscape
The 5HT3 receptor antagonists market is vast with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GlaxoSmithKline plc, Heron Therapeutics, Inc., Merck & Co., Inc., Eisai, Inc., Novartis Pharmaceuticals Corporation, Helsinn Holding S.A., Sanofi, Midatech Pharma US, Inc., Kyowa Kirin, Inc. and Tesaro, Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the 5HT3 receptor antagonists market globally.
5HT3 Receptor Antagonists Market Key Companies to Watch
Novartis Pharmaceutical Company:
Overview:
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is a publicly-traded Swiss holding company that operates through the Novartis Group. Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. Moreover, Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). It is one of the largest pharmaceutical companies in the world.
Product Portfolio:
Novartis Pharmaceutical Company has continuously set new standards for the manufacturing of products including Zofran ODT® (ondansetron), and Zofran® (ondansetron hydrochloride).
The global 5HT3 receptor antagonists market report would provide an access to an approx.47 market data tables, 39 figures and 180 pages.
